AstraZeneca plc (AZN) Expected to Post Earnings of $0.44 Per Share
Equities analysts expect AstraZeneca plc (NYSE:AZN) to post $0.44 earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for AstraZeneca’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.42. AstraZeneca reported earnings of $1.12 per share during the same quarter last year, which suggests a negative year over year growth rate of 60.7%. The business is expected to report its next quarterly earnings report before the market opens on Thursday, November 8th.
On average, analysts expect that AstraZeneca will report full-year earnings of $1.68 per share for the current year, with EPS estimates ranging from $1.65 to $1.70. For the next fiscal year, analysts forecast that the firm will post earnings of $1.89 per share, with EPS estimates ranging from $1.85 to $1.93. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow AstraZeneca.
AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.38. The firm had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.87 earnings per share.
Large investors have recently bought and sold shares of the stock. Bessemer Group Inc. lifted its position in shares of AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock worth $163,000 after buying an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $175,000. Tiverton Asset Management LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $178,000. Gilman Hill Asset Management LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $205,000. Finally, Independent Advisor Alliance purchased a new stake in AstraZeneca during the second quarter valued at approximately $206,000. Institutional investors own 15.98% of the company’s stock.
Shares of NYSE AZN traded up $0.11 during mid-day trading on Friday, reaching $37.18. The company’s stock had a trading volume of 2,167,175 shares, compared to its average volume of 3,887,245. The firm has a market cap of $93.89 billion, a price-to-earnings ratio of 8.69, a price-to-earnings-growth ratio of 2.00 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08. AstraZeneca has a 52 week low of $31.71 and a 52 week high of $39.76.
The company also recently announced a semiannual dividend, which will be paid on Monday, September 10th. Investors of record on Friday, August 10th will be given a $0.45 dividend. The ex-dividend date is Thursday, August 9th. This represents a dividend yield of 2.35%. AstraZeneca’s dividend payout ratio is currently 20.56%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: NASDAQ Stock Market Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.